Six reported cohorts, a total of 3416 patients, were used to analyze the mutation status of ARID1A, ARID1B, ARID2 and SMARCA4 in patients with NSCLC and the effect of mutations on prognosis after ICIs....Patients with an ARID1A or ARID1B mutation treated with ICIs had a median OS (mOS) of 21 months compared to 11 months for the WT group. Patients with an ARID2 mutation treated with ICIs had an mOS of 36 months compared to 11 months for the WT group...The results of this study demonstrated that patients with ARID1A, ARID1B, or ARID2 mutations were more likely to benefit from ICIs.

Patients harboring mutated ARID family members benefited more from ICI therapy (P = .0003)….NSCLC patients harboring ARID1B mutations (P = .0415) or ARID2 (P = .0236) mutations responded better to ICI therapy than wild-type patients.

Mutations in ARID1A and ARID1B were confirmed to be associated with sensitivity to ICIs. Patients harboring these mutations were found to have a better response to treatment (ARID1A: P = 0.045; ARID1B: P = 0.034) and prolonged progression-free survival (ARID1B: P = 0.032)....ARID1A and ARID1B could serve as novel biomarkers for the prognosis and sensitivity to ICIs of advanced NSCLC.